Actinium Pharmaceuticals (ATNM) - Utang jangka dawa marang modal

The readiness of Actinium Pharmaceuticals (ATNM) contract capacities for mass production confirms its manufacturing potential, which is reflected in the long-term debt-to-equity ratio within the GURU.Markets system. Innovations in targeted blood radiotherapy create a unique product, although isotope logistics complexities and regulation create risks. The value of 0.02 describes the current status of the long-term liabilities to equity metric.

This ratio determines the issuer's degree of financial stability by analyzing its liability structure. The metric compares the volume of credit obligations with a maturity of over one year against total equity. The trend of long-term liabilities as a share of equity allows for an assessment of the risk of excessive leverage. Maintaining this balance is critical for Actinium Pharmaceuticals (ATNM), as sustaining the complex aviation logistics of radiopharmaceuticals requires constant access to capital.